stockrowIDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.
- Revenue
- −95.1%
- EPS
- −190.5%
- Free cash flow
- −165.9%
Quarter to September 2026, against a year earlier
Follow IDYA
Alert me
IDEAYA Biosciences, Inc. (IDYA) EPS (diluted)
IDEAYA Biosciences, Inc.'s EPS (diluted) for fiscal 2025 was −$1.28, compared with −$3.36 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$4.49. Over the past ten years it has ranged from −$35.93 (fiscal 2018) to −$1.28 (fiscal 2025) — the current reading is the highest in ten years. IDEAYA Biosciences, Inc. ranks 432nd of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.28 | — |
| FY2024 | −$3.36 | — |
| FY2023 | −$1.96 | — |
| FY2022 | −$1.42 | — |
| FY2021 | −$1.41 | — |
| FY2020 | −$1.40 | — |
| FY2019 | −$3.36 | — |
| FY2018 | −$35.93 | — |
| FY2017 | −$17.07 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$1.22 | — |
| Jun 2026 | −$1.22 | — |
| Mar 2026 | −$1.11 | — |
| Dec 2025 | −$0.94 | — |
| 29 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| BEAM Beam Therapeutics Inc. compare | −$1.04 |
| ELVN Enliven Therapeutics, Inc. compare | −$1.67 |
| DNLI Denali Therapeutics Inc. compare | −$1.73 |
| DYN Dyne Therapeutics, Inc. compare | −$3.33 |
| VRDN Viridian Therapeutics, Inc. compare | −$3.37 |
| CELC Celcuity, Inc. compare | −$4.30 |
| IDYA IDEAYA Biosciences, Inc. | −$4.49 |
| TARS Tarsus Pharmaceuticals, Inc. compare | −$15.19 |
| TLX Telix Pharmaceuticals Limited compare | — |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on IDYA
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement